Maximizing dendritic cell migration in cancer immunotherapy.
BACKGROUND
The success of dendritic cell (DC)-based immunotherapy in inducing cellular immunity against tumors is highly dependent on accurate delivery and trafficking of the DC to T-cell-rich areas of secondary lymphoid tissues.


OBJECTIVE
To provide an overview of DC migration in vivo and how migration to peripheral lymph nodes might be improved to optimize DC therapy.


METHODS
We focused on DC migration in preclinical models and human skin explants and on clinical vaccination trials studying migration of in vitro-generated DC.


CONCLUSIONS
DC migration requires an intricate interplay between the cell and its environment. To maximize migration for cellular therapy, it is important to optimize the generation of migratory DC as well as treatment strategies.
Radboud University Nijmegen Medical Centre, Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Geert Grooteplein 28, Nijmegen, The Netherlands.
Pauline
P
Verdijk
Erik H J G
EH
Aarntzen
Cornelis J A
CJ
Punt
I Jolanda M
IJ
de Vries
Carl G
CG
Figdor
D000818:Animals; D019496:Cancer Vaccines; D002448:Cell Adhesion; D002465:Cell Movement; D018925:Chemokines / Q000378:metabolism; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000166:cytology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008198:Lymph Nodes / Q000378:metabolism; D008207:Lymphatic Metastasis; D051379:Mice; D009000:Monocytes / Q000166:cytology; D009369:Neoplasms / Q000628:therapy*; D012867:Skin / Q000378:metabolism
D019496:Cancer Vaccines; D018925:Chemokines